The final, formatted version of the article will be published soon.
CLINICAL TRIAL article
Front. Cardiovasc. Med.
Sec. General Cardiovascular Medicine
Volume 11 - 2024 |
doi: 10.3389/fcvm.2024.1462730
Efficacy and Safety of Danlou Tablets in the Treatment of Stable Angina Pectoris with Intermingled Phlegm and Blood Stasis Syndrome in Coronary Heart Disease: A Multicenter, Practical Randomized Controlled Study
Provisionally accepted
Zeng Li
1*
Han Li
2
Zheng Li
3
Yushi Zhou
1
Yang Wei
4
Yuhan Ao
1*
Xinghua Xiang
4*
Chongchai Li
1*
Mingxue Zhang
3*- 1 Liaoning University of Traditional Chinese Medicine, Shenyang, China
- 2 Shenyang Health Service Center, Shenyang, China
- 3 Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, China
- 4 Institute of Clinical Medicine#Basic sciences, Chinese Academy of Traditional Chinese Medicine, Beijing, China
Objectives: In this study, we assessed the clinical efficacy and safety of Danlou tablets in the treatment of stable angina pectoris (SAP) with intermingled phlegm and blood stasis(IPBS), to provide high-quality evidence-based medical evidence for the prevention and treatment of Coronary Heart Disease. Methods: In the multicenter, practical randomized controlled study, 304 patients diagnosed with stable angina pectoris with IPBS enrolled from 12 national traditional Chinese medicine (TCM) clinical research centers in China, were randomly assigned to the treatment group and the control group at a ratio of 1:1. Each group was divided into four subgroups based on the results of TCM syndrome differentiation: IPBS, IPBS combined with qi deficiency(IPBS-QD), IPBS combined with qi stagnation(IPBS-QS), and IPBS combined with toxin accumulation(IPBS-TA). The control group was treated with routine Western medicine. Based on routine Western medicine treatment, the treatment group was treated with Danlou tablets (IPBS) or
Keywords: coronary heart disease, Stable angina pectoris, Syndrome of mutual accumulation of phlegm and blood stasis, Danlou tablets, Randomized controlled
Received: 10 Jul 2024; Accepted: 04 Oct 2024.
Copyright: © 2024 Li, Li, Li, Zhou, Wei, Ao, Xiang, Li and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zeng Li, Liaoning University of Traditional Chinese Medicine, Shenyang, China
Yuhan Ao, Liaoning University of Traditional Chinese Medicine, Shenyang, China
Xinghua Xiang, Institute of Clinical Medicine#Basic sciences, Chinese Academy of Traditional Chinese Medicine, Beijing, China
Chongchai Li, Liaoning University of Traditional Chinese Medicine, Shenyang, China
Mingxue Zhang, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.